Article
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
PloS one - 1 Jan 2016
Wedemeyer Heiner, Forns Xavier, Hézode Christophe, Lee Samuel S, Scalori Astrid, Voulgari Athina, Le Pogam Sophie, Nájera Isabel, Thommes James A
Abstract excerpt
UNLABELLED: Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (<2-log10 reduction in HCV RNA by treatment week 12) to peginterferon/ribavirin (PegIFN/RBV) do not achieve a sustained virological response (SVR) when re-treated with a first-generation HCV protease inhibitor (PI) administered in combination with PegIFN/RBV. We studied the incremental...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.